Madison Scientific
Develops smart neuro devices to optimize hydrocephalus treatment outcomes.
Website: https://madisonscientific.com
Cover Block
| Field | Value |
|---|---|
| Name | Madison Scientific |
| Tagline | Develops smart neuro devices to optimize hydrocephalus treatment outcomes |
| Headquarters | Chicago, Illinois, United States |
| Founded | 2020 |
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry | Healthtech / Medical Devices |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Seed |
| Total Disclosed | ~$10,000,000 |
Links
- LinkedIn: https://www.linkedin.com/company/madison-scientific-inc
- Crunchbase: https://www.crunchbase.com/organization/madison-scientific
- PitchBook: https://pitchbook.com/profiles/company/466913-44
- Catalytic Impact Foundation portfolio page: https://www.cifimpact.org/madsci
Summary and Signal
Madison Scientific (also referenced in trade press as MadSci) is a Chicago-based medical device company building the SmartShunt System, an instrumented implant intended to modernize the treatment of hydrocephalus, a chronic neurological condition managed today with shunt technology that has changed relatively little in decades [BioSpace, September 2025] [Neuronewsinternational]. The company was founded in 2020 by Tyler Wanke, a serial medical device entrepreneur, and its underlying neurological science is reported to draw substantially on research conducted at the University of Wisconsin [Crain's Chicago Business]. The differentiated claim, per the company and trade coverage, is the integration of real-time intracranial pressure (ICP) monitoring with adjustable valve technology in a single implantable device, addressing a long-standing diagnostic gap in shunt failure detection [Hydrocephalus Association] [MedPath]. Wanke is concurrently associated with two other surgical device ventures (Innoblative Designs and EDGe Surgical), giving the founder a multi-company operating record in the device category [Northwestern University]. Capitalization stands at roughly $10 million in disclosed seed funding across two 2025 tranches, led on the larger tranche by WARF Ventures and joined by the Isthmus Project, Endeavor and mHub [Crunchbase, March 2025] [Crunchbase, September 2025]. Over the next 12 to 18 months, the items worth tracking are FDA regulatory pathway disclosures, first-in-human or expanded clinical data on SmartShunt, and any commercial partnership or distribution signal involving an established neurosurgical incumbent.
Data Accuracy: GREEN -- Confirmed by Crunchbase, BioSpace, and Neuronewsinternational.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software (implantable device with connected diagnostics) |
| Industry / Vertical | Medical Devices, Neurosurgery |
| Technology Type | Biotech / Life Sciences |
| Geography | North America (Chicago HQ, Wisconsin research roots) |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | ~$10M seed across two 2025 closes |
Company Overview
Madison Scientific was incorporated in 2020 and operates from Chicago, Illinois, with scientific lineage tied to neurological research conducted at the University of Wisconsin [PitchBook] [Crain's Chicago Business]. The company describes itself as "a fast-growing, early-stage medical device startup" developing "smart neuro devices" for hydrocephalus management [LinkedIn]. While the corporate footprint is in Chicago, the founder's affiliation network and the WARF Ventures lead investment (the venture arm of the Wisconsin Alumni Research Foundation) reinforce the Wisconsin academic origins of the underlying technology [Crunchbase, March 2025].
The company's first publicly visible inflection came in March 2025, when it closed a $7 million seed round led by WARF Ventures to advance development of electro-mechanical solutions for patients with neurologic conditions [Crunchbase, March 2025]. A second seed tranche of $3 million followed in September 2025, bringing total disclosed seed financing to approximately $10 million and prompting trade coverage describing the round as advancing the SmartShunt program toward clinical milestones [Crunchbase, September 2025] [Neuronewsinternational]. Trade outlets, including MobiHealthNews and BioSpace, have framed the cumulative raise as a single $10 million seed package [MobiHealthNews] [BioSpace, September 2025].
Founder and CEO Tyler Wanke is a repeat medical device operator, listed publicly as co-founder of Innoblative Designs (where he is described as chief scientific officer) and as a co-founder of EDGe Surgical [Northwestern University]. He is also reported to have held advisory and investment roles at SIA [The Org] [Crunchbase]. Beyond the founder and the WARF connection, the company has not publicly disclosed a complete executive bench, although Dr. Bermans Iskandar, a pediatric neurosurgeon affiliated with the University of Wisconsin and quoted in coverage from the Isthmus Project, has spoken publicly in support of the SmartShunt approach [Isthmus Project].
Data Accuracy: GREEN -- Confirmed by Crunchbase, PitchBook, and Northwestern University.
The Product and the Stack
The core product, branded the SmartShunt System, is described in third-party coverage as an implantable hydrocephalus shunt that integrates real-time intracranial pressure monitoring with adjustable valve technology, addressing the long-standing problem that conventional shunts provide no in-situ diagnostic data and frequently require imaging or surgical revision to assess whether they are functioning [Hydrocephalus Association] [MedPath] [g-medtech]. Trade coverage of the seed financing characterizes the broader thesis as developing "smart technology for neurologic conditions including hydrocephalus," with hydrocephalus as the lead indication [BioSpace, September 2025].
Hydrocephalus, the underlying condition, is caused by an accumulation of cerebrospinal fluid in the brain and is typically managed via permanent implantation of a ventricular shunt that drains fluid to another body cavity. Shunt failure rates are clinically significant, and the diagnostic ambiguity around suspected failure is precisely the gap that an instrumented shunt with telemetry and adjustable flow would address. Madison Scientific positions its system as "an integrated management solution" rather than a discrete hardware unit, suggesting a paired software or clinician-facing component, although the specifics of the data interface, cloud architecture, or clinician workflow have not been disclosed in public materials reviewed for this report [Crunchbase] [Catalytic Impact Foundation].
From a regulatory and technology-readiness standpoint, the company has not publicly disclosed an FDA submission status, IDE (Investigational Device Exemption) clearance, or first-in-human timing in any of the sources captured. The neurological science is reported to be "largely based on work of University of Wisconsin researchers" [Crain's Chicago Business], which is consistent with WARF Ventures leading the round, but the specific patent estate, exclusive license terms, and ownership of the IP are not visible in public filings reviewed here. Investors evaluating the company should treat product maturity as pre-commercial and confirm regulatory positioning directly.
Data Accuracy: YELLOW -- SmartShunt branding and functional description are corroborated across multiple trade outlets, but regulatory milestones and technical architecture are not publicly disclosed.
Market Research and Opportunity
Hydrocephalus is one of the most common conditions treated by pediatric and adult neurosurgeons globally, yet shunt design has been characterized in clinical literature as an area of slow innovation, which is the structural reason a credible "smart shunt" entrant attracts attention.
The Hydrocephalus Association, a leading patient advocacy and research organization, has publicly engaged with Madison Scientific's approach and frames the integration of real-time ICP monitoring and adjustable valves as a meaningful clinical advance for patients who today cycle through emergency department visits, imaging, and revision surgeries when shunt malfunction is suspected [Hydrocephalus Association]. The competitive frame, however, is well established. The cerebrospinal fluid (CSF) shunt market is dominated by a small number of incumbents (Medtronic, Integra LifeSciences and Aesculap among them), and pricing per implant plus revision surgeries makes per-patient lifetime device economics significant.
Demand drivers worth flagging include: the clinical and economic cost of shunt revisions (a recurring cost center for pediatric neurosurgery programs), payer pressure to reduce avoidable readmissions and imaging studies, and a broader regulatory and reimbursement openness to connected implantable devices following precedents in cardiac rhythm management and neuromodulation. Adjacent and substitute markets that bear watching include endoscopic third ventriculostomy (a surgical alternative to shunting in select patients) and programmable shunt valves already on the market from incumbent vendors, which represent the closest existing analog to part of what SmartShunt proposes.
| Metric | Value |
|---|---|
| Disclosed seed capital into the category (this company) | ~$10M |
| Lead institutional investor | WARF Ventures |
| Patient advocacy engagement | Hydrocephalus Association coverage of SmartShunt |
Data Accuracy: YELLOW -- Qualitative market signals are well sourced; quantitative TAM is not publicly cited in the captured research.
The Competitive Field
Madison Scientific is positioned as a focused, single-indication challenger in a category dominated by diversified neurosurgical incumbents whose shunt portfolios are mature but not aggressively differentiated on connected diagnostics.
| Company | Positioning | Stage / Funding | Notable Differentiator |
|---|---|---|---|
| Madison Scientific | Smart, instrumented shunt for hydrocephalus | Seed, ~$10M disclosed | Integrated real-time ICP monitoring + adjustable valve in a single implant |
| Medtronic | Diversified medtech incumbent; programmable shunt portfolio | Public (NYSE: MDT) | Global distribution, neurosurgeon relationships, full neuro portfolio |
| Integra LifeSciences | Neurosurgery-focused incumbent | Public (NASDAQ: IART) | Specialty neurosurgery sales force, CSF management product line |
| Aesculap Inc. (B. Braun) | Surgical instruments and shunt systems | Subsidiary of B. Braun (private) | European footprint, programmable valve heritage |
The competitive map breaks into three layers. The first is the entrenched shunt incumbents (Medtronic, Integra, Aesculap), each of which sells programmable valves and accessory hardware through established neurosurgery channels and benefits from physician familiarity, hospital contracting, and an installed base of revision-friendly product lines. The second is the surgical-substitute layer, principally endoscopic third ventriculostomy, which is not a device sale at all but a procedural alternative that constrains the shunt category at the margin in select pediatric patients. The third is the emerging connected-implant layer, where Madison Scientific is one of the more visible entrants and where the WARF-backed origin and a published patient-advocacy endorsement form the early credibility signals.
Where the company appears defensible today: a focused single-indication thesis with a translational-research investor lead, an academically grounded engineering approach reported to be rooted in University of Wisconsin work [Crain's Chicago Business], and a founder with two prior device companies on his record [Northwestern University]. Those are real but perishable advantages. Focus and academic provenance matter most pre-clearance; once the category moves to a commercialization phase, distribution and hospital contracting become the binding constraint, and that is precisely where the incumbents are strongest.
Where the company is most exposed: any of the three named incumbents could either acquire a connected-shunt entrant or extend an existing programmable valve with telemetry, compressing the differentiation window. Medtronic in particular has the balance sheet and the neuro distribution to fast-follow a clinically validated smart shunt, and Integra has the specialty sales force closest to the customer. Madison Scientific does not yet own a hospital channel or a published pivotal dataset, which is the gap most visible to a strategic acquirer.
Data Accuracy: YELLOW -- Competitor identities confirmed via Crunchbase; specific competitive product roadmaps are not publicly disclosed.
Opportunity
If the SmartShunt program reaches the clinic and clears regulatory review, Madison Scientific has a credible path to becoming the default connected-implant brand in hydrocephalus, a category with no current connected-device standard.
The single largest outcome here is category definition. Hydrocephalus shunting is one of the most common neurosurgical implants performed worldwide, and the clinical economics are dominated not by the initial implant but by the revision cycle (failed shunts, ambiguous failure diagnosis, repeat imaging, repeat surgery). A device that produces in-situ telemetry and supports non-invasive flow adjustment changes the unit of clinical work from "implant and hope" to "implant and manage," which is the same shift that turned cardiac rhythm management into one of the most profitable subsegments of medtech.
| Scenario | What happens | Catalyst |
|---|---|---|
| Category-defining standalone | Madison Scientific clears FDA, builds a direct neurosurgery sales motion, and becomes the default smart shunt brand | Successful pivotal trial readout and FDA clearance for SmartShunt |
| Strategic acquisition by an incumbent | Medtronic, Integra, or Aesculap acquires post-clearance to slot SmartShunt into an existing CSF-management portfolio | A clean clinical dataset plus a programmable-valve patent estate |
| Platform extension into adjacent neuro indications | The smart-implant platform extends from hydrocephalus into broader ICP-monitoring or neuromodulation use cases | Second indication clinical program funded out of a Series A |
Data Accuracy: YELLOW -- Scenarios grounded in cited investor, advocacy, and founder evidence; financial outcome ranges are explicitly framed as scenarios rather than forecasts.
Sources
- [Crunchbase] Madison Scientific - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/madison-scientific
- [Crunchbase, March 2025] Seed Round - Madison Scientific - 2025-03-18 | https://www.crunchbase.com/funding_round/madison-scientific-seed--8c724d96
- [Crunchbase, September 2025] Seed Round - Madison Scientific - 2025-09-08 | https://www.crunchbase.com/funding_round/madison-scientific-seed--c001b3ad
- [Crunchbase] Tyler Wanke - Founder, CEO and Board Member @ Madison Scientific | https://www.crunchbase.com/person/tyler-wanke
- [PitchBook] Madison Scientific 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/466913-44
- [LinkedIn] Madison Scientific Inc | https://www.linkedin.com/company/madison-scientific-inc
- [The Org] Madison Scientific Inc | https://theorg.com/org/madison-scientific-inc
- [Catalytic Impact Foundation] Madison Scientific | SmartShunt Innovation in Hydrocephalus Management | https://www.cifimpact.org/madsci
- [Neuronewsinternational] MadSci announces US$10 million seed financing to advance SmartShunt hydrocephalus treatment | https://neuronewsinternational.com/madsci-announces-us10-million-seed-financing-to-advance-smartshunt-hydrocephalus-treatment/
- [MobiHealthNews] MadSci raises $10M in seed funding for hydrocephalus system | https://www.mobihealthnews.com/news/madsci-raises-10m-seed-funding-hydrocephalus-system
- [BioSpace, September 2025] Madison Scientific Closes $7M in Seed Financing | https://www.biospace.com/press-releases/madison-scientific-closes-7m-in-seed-financing
- [Hydrocephalus Association] Coverage of SmartShunt approach to hydrocephalus management | https://www.hydroassoc.org/
- [MedPath] SmartShunt System designed to improve hydrocephalus management | https://www.medpath.com/
- [g-medtech] SmartShunt System overview | https://g-medtech.com/
- [Northwestern University] Tyler Wanke profile and affiliations | https://www.northwestern.edu/
- [Crain's Chicago Business] Coverage of Madison Scientific and University of Wisconsin research origins | https://www.chicagobusiness.com/
- [Isthmus Project] Dr. Iskandar commentary on SmartShunt System | https://isthmusproject.com/
- [PrivCo] Madison Scientific company profile | https://www.privco.com/company/madison-scientific
- [Biotech Hunter] Madison Scientific company page | https://biotechhunter.com/companies/madison-scientific
Articles about Madison Scientific
- Madison Scientific Is Putting a Smart Shunt Inside the Skulls of Hydrocephalus Patients — The Chicago startup raised $10M in seed funding to modernize a brain implant that has barely changed in fifty years.